Background
==========

Ceftriaxone, cefotaxime, and cefepime minimum inhibitory concentration (MIC) interpretive breakpoints for meningeal and nonmeningeal isolates of *Streptococcus pneumoniae*were published in January 2002 by the National Committee for Clinical Laboratory Standards (NCCLS) in their M100-S12 document \[[@B1]\]. Previously, a single set of breakpoints was used to interpret ceftriaxone, cefotaxime, and cefepime MICs for both meningeal and nonmeningeal *S. pneumoniae*isolates \[[@B2]\]. These breakpoints were initially published in 1996 and remained unchanged through December 2001. For ceftriaxone and cefotaxime, the M100-S12 guidelines advise laboratories to report both meningeal and nonmeningeal interpretations for pneumococcal isolates recovered from body sites other than cerebrospinal fluid. Ceftriaxone and cefotaxime MICs for isolates from cerebrospinal fluid should be reported with meningitis interpretative criteria only. Since cefepime does not have an approved indication for meningitis in the U.S., the recommendation is to report only the nonmeningitis interpretations for this agent \[[@B1]\]. A previous study based on historical data showed the M100-S12 ceftriaxone and cefotaxime interpretive breakpoints for nonmeningeal isolates decreased the number of *S. pneumoniae*isolates interpreted as intermediate by 10% and as resistant by 3 to 4% \[[@B3]\]. A second study, by Jones and colleagues, showed a 9.1 to 13.0% increase in susceptibility to cefotaxime, ceftriaxone, and cefepime using the M100-S12 nonmeningeal interpretive criteria \[[@B4]\]. The current study was conducted to determine the rate at which a set of clinical laboratories in the United States adopted the M100-S12 interpretive breakpoint changes from January 2002 to June 2003.

Methods
=======

The Surveillance Network Database -- USA (TSN), an electronic database that collects MICs, MIC categorical interpretation data, and other microbiology laboratory data from 326 U.S. clinical microbiology laboratories, was used as the source of antimicrobial susceptibility test data \[[@B5]\]. Nonmeningeal isolates of *S. pneumoniae*were limited to those isolated from blood and respiratory tract sources. Respiratory tract isolates included those from both the upper and lower respiratory tracts. Ceftriaxone and cefotaxime MICs and corresponding susceptible, intermediate, and resistant interpretations were cross-referenced to determine if laboratories used the M100-S11 \[[@B2]\] or the M100-S12 \[[@B1]\] nonmeningeal *S. pneumoniae*MIC interpretive breakpoints to interpret the MICs they generated. Cefepime was not included in this analysis as only 16 laboratories reported results (*n*= 572) for this agent. Sixty-four TSN laboratories did not report assessable data for ceftriaxone or cefotaxime during the time period of the study. Laboratories were not assessable if they did not test cefotaxime or ceftriaxone against *S. pneumoniae*or did not report MIC values of 1 or 2 μg/ml. The breakpoint standard used could only be inferred when MIC values of 1 or 2 μg/ml were obtained.

In addition, a questionnaire was sent to laboratories in September 2002, inquiring if the M100-S12 nonmeningeal breakpoints were in use at their laboratory. Laboratories that had not adopted the new breakpoints were asked why the changes had not been implemented, if they would be implemented, and when they would be implemented. Only laboratories that had assessable MIC data and returned a completed questionnaire were included in the analysis of the questionnaire data set.

To determine the effect of not adopting the new interpretations, MICs from 12,827 nonmeningeal isolates of *S. pneumoniae*tested against ceftriaxone and cefotaxime from January 2002 to June 2003 were evaluated and susceptible, intermediate, and resistant interpretation rates for ceftriaxone and cefotaxime were calculated using both the M100-S11 and M100-S12 breakpoints.

Results
=======

Two hundred sixty-two TSN laboratories were included in the overall analysis. One hundred and seventy-four laboratories were included in the analysis for ceftriaxone and 200 laboratories were included for cefotaxime. Table [1](#T1){ref-type="table"} compares the number of laboratories with interpretable data that were using the M100-S11 or M100-S12 criteria by quarter from January 2002 to June 2003. Cross-referencing quantitative (MICs) and qualitative (susceptible, intermediate, resistant) data showed that at the end of January 2002, 13.1% (11/84) of laboratories reporting ceftriaxone results and 17.4% (22/126) of laboratories reporting cefotaxime results used the new M100-S12 breakpoints (data not shown). The proportion of laboratories using the M100-S12 breakpoints for ceftriaxone and cefotaxime increased an average of 3% per month from January 2002 to June 2003. By September 2002, 36% (90/250) of laboratories reporting results for expanded-spectrum cephalosporins used the M100-S12 breakpoints.

###### 

Implementation of NCCLS M100-S12 MIC breakpoints for expanded-spectrum cephalosporins tested against nonmeningeal isolates of *S. pneumoniae*by US clinical laboratories from January 2002 to June 2003

                                                                Number of laboratories (%) using the following breakpoints:                  
  ------------------------------- ----------------------- ----- ------------------------------------------------------------- -------- ----- --------
  Ceftriaxone and/or cefotaxime   January-March 2002      216   168                                                           (77.8)   48    (22.2)
                                  April-June 2002         231   157                                                           (68.0)   74    (32.0)
                                  July-September 2002     250   160                                                           (64.0)   90    (36.0)
                                  October-December 2002   256   147                                                           (57.4)   109   (42.6)
                                  January-March 2003      260   135                                                           (51.9)   125   (48.1)
                                  April-June 2003         262   85                                                            (32.4)   177   (67.6)
  Ceftriaxone                     January-March 2002      119   93                                                            (78.2)   26    (21.8)
                                  April-June 2002         135   82                                                            (60.7)   53    (39.3)
                                  July-September 2002     163   94                                                            (57.7)   69    (42.3)
                                  October-December 2002   166   92                                                            (55.4)   74    (44.6)
                                  January-March 2003      172   78                                                            (45.3)   94    (54.7)
                                  April-June 2003         174   82                                                            (47.1)   92    (52.9)
  Cefotaxime                      January-March 2002      158   142                                                           (89.9)   16    (10.1)
                                  April-June 2002         168   143                                                           (85.1)   25    (14.9)
                                  July-September 2002     186   159                                                           (85.5)   27    (14.5)
                                  October-December 2002   196   141                                                           (71.9)   55    (28.1)
                                  January-March 2003      200   137                                                           (68.5)   63    (31.5)
                                  April-June 2003         200   96                                                            (48.0)   104   (52.0)

One hundred seventy-three of 262 laboratories (66.0%) responded to the questionnaire sent in September 2002. Among the laboratories responding to the questionnaire, 53.2% (92/173) stated they were using the M100-S12 breakpoints and 46.8% (81/173) of laboratories had not yet adopted the new breakpoints. Of the respondents that were not using the M100-S12 breakpoints, nearly one-half attributed this to difficulty in modifying their laboratory information system (LIS) or to not having information systems staff available to make the necessary changes. Thirty-six percent (29/81) of the responding laboratories that stated they were not currently using the new breakpoints reported that they planned to adopt the new breakpoints by the end of 2002.

By the end of 2002, 42.6% (109/256) of laboratories with data that could be evaluated had adopted the M100-S12 nonmeningeal *S. pneumoniae*cefotaxime or ceftriaxone interpretive breakpoints and 57.4% (147/256) of laboratories continued to use the M100-S11 breakpoints. The laboratories that adopted the M100-S12 breakpoints included 44.6% (74/166) of laboratories reporting ceftriaxone and 28.1% (55/196) of laboratories reporting cefotaxime. By June 2003, 67.6% (177/262) of laboratories with data that could be evaluated had adopted the M100-S12 nonmeningeal *S. pneumoniae*cefotaxime or ceftriaxone interpretive breakpoints and 32.4% (85/262) of laboratories continued to use the M100-S11 breakpoints. The laboratories that adopted the M100-S12 breakpoints included 52.9% (92/174) of laboratories reporting ceftriaxone and 52.0% (104/200) of laboratories reporting cefotaxime. One hundred and twelve of 262 laboratories tested both ceftriaxone and cefotaxime, 88 laboratories tested only cefotaxime, and 62 laboratories tested only ceftriaxone in April-June 2003.

Ceftriaxone (*n*= 7,940) and cefotaxime (*n*= 4,887) MICs for nonmeningeal *S. pneumoniae*isolates were interpreted by applying both the M100-S11 and the M100-S12 interpretive criteria (Table [2](#T2){ref-type="table"}). The proportion of isolates interpreted as susceptible increased by 9.9% for ceftriaxone and 13.5% for cefotaxime when interpreted using M100-S12 nonmeningeal breakpoints. The proportion of isolates interpreted as intermediate decreased by 7.6% and 10.9% and the proportion of isolates interpreted as resistant decreased by 2.2% and 2.6% for ceftriaxone and cefotaxime, respectively, when interpreted using M100-S12 nonmeningeal breakpoints.

Conclusions
===========

Based on MIC and MIC interpretation data submitted by participating TSN laboratories, we conclude that 67.6% of all laboratories with interpretable data for *S. pneumoniae*tested against expanded-spectrum cephalosporins had implemented the M100-S12 breakpoints by June 2003. Approximately one-half (52.9%) of the laboratories with interpretable data for *S. pneumoniae*and ceftriaxone and 52.0% of laboratories reporting cefotaxime had implemented the M100-S12 breakpoints by June 2003. The adoption of the M100-S12 breakpoints is more difficult for laboratories to implement than previous NCCLS interpretive breakpoints as laboratory information systems were not designed to accommodate reporting multiple breakpoints for a single organism-antimicrobial agent combination. Also, as this is the first instance of multiple specimen source-specific interpretive breakpoints for a single organism-antimicrobial agent combination, education of laboratory staff and clinicians was required, likely further complicating the implementation of the new criteria. Continued use of the M100-S11 breakpoints for expanded-spectrum cephalosporins may lead to the reporting of false in vitro non-susceptibility of nonmeningeal *S. pneumoniae*isolates. Application of the new interpretative criteria, with higher breakpoints for nonmeningeal isolates, will result in an increase in the number of *S. pneumoniae*isolates reported as susceptible to cefotaxime and ceftriaxone (Table [2](#T2){ref-type="table"}) \[[@B2],[@B4]\]. Based on analysis of data from January 2002 to June 2003, approximately 10--15% more nonmeningeal isolates will be reported as susceptible when the M100-S12 breakpoints are used. The publication and use of the M100-S12 breakpoints to interpret meningeal and nonmeningeal isolates of *S. pneumoniae*will more accurately reflect the clinical activities of these agents where the use of an expanded-spectrum cephalosporin is indicated.

###### 

Susceptibility of nonmeningeal isolates of *S. pneumoniae*recovered from January 2002 to June 2003 to expanded-spectrum cephalosporins using both M100-S11 and M100-S12 NCCLS standards

  Antimicrobial agent   Total no. of isolates   NCCLS standard   \% Susceptible   \% Intermediate   \% Resistant
  --------------------- ----------------------- ---------------- ---------------- ----------------- --------------
  Ceftriaxone           7,940                   M100-S11         86.9             9.9               3.2
                                                M100-S12         96.8             2.3               1.0
  Cefotaxime            4,887                   M100-S11         82.4             13.5              4.1
                                                M100-S12         95.9             2.6               1.5
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